Company News

Evonik Invests in BioTech Startup with Peptides Expertise

Numaferm technology enables plannable biotechnological production of peptides at higher yield, lower costs.

Author Image

By: Christine Esposito

Editor-in-Chief

Through its venture capital unit, Evonik has invested in the start-up Numaferm and now holds a minority share in the biotechnology company. The investment in the Düsseldorf-based company was made as part of a seed financing round and also includes investments by High-Tech Gründerfonds, the Business Angels and Qiagen co-founders Detlev Riesner and Jürgen Schumacher, as well as the European Investment Fund. “Peptides and their applications are highly interesting for our growth engines hea...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters